Researcher index

Authors in the psilocybin and psilocin literature

Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.

Anna C. Beck

38 indexed publications match this author name.

ORCID: 0000-0003-0592-9540
OpenAlex: https://openalex.org/A5054078305

Author watchlist

Create a confirmed email alert for new publications matching this author.

Topics

Pharmacology 13 Depression 12 Healthy Volunteers 12 Clinical Trial 11 Anxiety 10 Safety 8 Mechanism of Action 6 Consciousness 5 Toxicity 5 Observational Study 5 Adverse Events 4 Mystical Experience 4

Journals

Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 3 ClinicalTrials.gov 3 Clinical pharmacology and therapeutics 3 Journal of psychopharmacology (Oxford, England) 2 Neuroscience Applied 2 Psychopharmacology 2 Neuroscience of consciousness 1 JAMA Network Open 1

Publication history

CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2026-09-01 Low-dose lysergic acid diethylamide alters subjective visual perception but not visual contrast surround suppression.Neuroscience of consciousness · 2026-08-20 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major DepressionJAMA Network Open · 2026-05-15 The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.Journal of psychopharmacology (Oxford, England) · 2026-05-01 Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled SettingsRepository for Publications and Research Data (ETH Zurich) · 2026-04-30 Additional file 1 of Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depressionFigshare · 2026-04-09 Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depressionBMC Medical Education · 2026-04-09 Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness-a psychometric analysis using the PES100 in controlled psychedelic studiesReligion Brain & Behavior · 2026-03-31 Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy VolunteersClinicalTrials.gov · 2026-02-05 Psychedelics distinctly alter brain entropy and complexity compared to psychostimulantsmedRxiv · 2026-01-16 Symptom-level antidepressant response to psilocybin: exploratory outcomes comparing psilocybin treatment to niacinNeuroscience Applied · 2026-01-01 "Wood-lover paralysis": Describing a toxidrome with symptoms of weakness caused by some lignicolous "wood-loving" Psilocybe mushrooms.Toxicon: official journal of the International Society on Toxinology · 2025-09-01 “Wood-lover paralysis”: Describing a toxidrome with symptoms of weakness caused by some lignicolous “wood-loving” Psilocybe mushroomsToxicon · 2025-09-01 Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.Psychopharmacology · 2025-08-01 Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial.Clinical pharmacology and therapeutics · 2025-06-01 [Psychedelic psychiatry].Lakartidningen · 2024-04-04 The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.Journal of psychopharmacology (Oxford, England) · 2024-01-01 Safety pharmacology of acute psilocybin administration in healthy participants.Neuroscience applied · 2024-01-01 Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2023-10-01 HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer.Journal of pain and symptom management · 2023-09-01 Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants.Clinical pharmacology and therapeutics · 2023-04-01 Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trialJournal of Psychedelic Studies · 2023-01-18 Psychedelic Assisted Psychotherapy preparing your target using psychohistoriography: a Jamaican perspective.Frontiers in psychiatry · 2023-01-01 An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)ClinicalTrials.gov · 2022-10-12 Group Format Psilocybin-Assisted Therapy: Commentary on the HOPE trial (HOPE: a pilot study of psilocybin-enhanced group psychotherapy in patients with cancer)Journal of Anesthesiology and Pain Therapy · 2022-10-03 Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice.Translational psychiatry · 2022-08-11 Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants.Psychopharmacology · 2022-06-01 Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2022-05-01 Psychoactive Drugs in the Management of Post Traumatic Stress Disorder: A Promising New Horizon.Cureus · 2022-05-01 Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.Clinical pharmacology and therapeutics · 2022-04-01 Pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of oral psilocybin administration in healthy subjectsNeuroscience Applied · 2022-01-01 Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives.Frontiers in psychology · 2022-01-01 "Hallucinations" Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs.Cannabis and cannabinoid research · 2018-01-01 Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project.Scandinavian journal of clinical and laboratory investigation · 2013-08-01 Bioanalytical and clinical evaluation of 103 suspected cases of intoxications with psychoactive plant materials.Clinical toxicology (Philadelphia, Pa.) · 2009-07-01 A multi-component LC-MS/MS method for detection of ten plant-derived psychoactive substances in urine.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2009-04-15 Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions.Journal of analytical toxicology · 1998-01-01

Author directory